Katharina C. Kaehler

4.5k total citations
23 papers, 629 citations indexed

About

Katharina C. Kaehler is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Katharina C. Kaehler has authored 23 papers receiving a total of 629 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 10 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Katharina C. Kaehler's work include Cutaneous Melanoma Detection and Management (10 papers), Melanoma and MAPK Pathways (8 papers) and CAR-T cell therapy research (5 papers). Katharina C. Kaehler is often cited by papers focused on Cutaneous Melanoma Detection and Management (10 papers), Melanoma and MAPK Pathways (8 papers) and CAR-T cell therapy research (5 papers). Katharina C. Kaehler collaborates with scholars based in Germany, United States and Switzerland. Katharina C. Kaehler's co-authors include Axel Hauschild, Dirk Schadendorf, Friederike Egberts, Elisabeth Livingstone, Bastian Schilling, Sarah Piel, Selma Ugurel, Reinhard Dummer, Claus Garbe and Uwe Trefzer and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

Katharina C. Kaehler

23 papers receiving 604 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Katharina C. Kaehler Germany 15 319 240 232 64 47 23 629
Annette Stein Germany 10 128 0.4× 187 0.8× 182 0.8× 76 1.2× 29 0.6× 32 509
Chao Yao China 14 141 0.4× 218 0.9× 281 1.2× 31 0.5× 40 0.9× 30 497
Ying Lu China 15 218 0.7× 222 0.9× 85 0.4× 14 0.2× 24 0.5× 58 538
I Spuz̈ić Serbia 15 227 0.7× 133 0.6× 507 2.2× 17 0.3× 48 1.0× 51 795
Xiaoling Yu China 13 100 0.3× 214 0.9× 184 0.8× 34 0.5× 35 0.7× 36 507
Antônio da Silva United States 12 166 0.5× 178 0.7× 293 1.3× 29 0.5× 15 0.3× 20 559
Masayuki Ishizaki Japan 13 130 0.4× 89 0.4× 367 1.6× 15 0.2× 111 2.4× 17 726
Hongyu Zhao China 13 171 0.5× 273 1.1× 212 0.9× 10 0.2× 58 1.2× 34 840
Mariola Sadowska United States 16 384 1.2× 279 1.2× 71 0.3× 28 0.4× 62 1.3× 28 789
Leslie Douglas United States 11 176 0.6× 476 2.0× 114 0.5× 8 0.1× 41 0.9× 13 589

Countries citing papers authored by Katharina C. Kaehler

Since Specialization
Citations

This map shows the geographic impact of Katharina C. Kaehler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Katharina C. Kaehler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Katharina C. Kaehler more than expected).

Fields of papers citing papers by Katharina C. Kaehler

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Katharina C. Kaehler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Katharina C. Kaehler. The network helps show where Katharina C. Kaehler may publish in the future.

Co-authorship network of co-authors of Katharina C. Kaehler

This figure shows the co-authorship network connecting the top 25 collaborators of Katharina C. Kaehler. A scholar is included among the top collaborators of Katharina C. Kaehler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Katharina C. Kaehler. Katharina C. Kaehler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bhave, Prachi, Lalit Pallan, Victoria Atkinson, et al.. (2020). Melanoma recurrence after adjuvant targeted therapy: A multicenter analysis.. Journal of Clinical Oncology. 38(15_suppl). 10016–10016. 3 indexed citations
2.
Loquai, Carmen, Marlene Garzarolli, Martin Kaatz, et al.. (2016). Use of complementary and alternative medicine: A multicenter cross-sectional study in 1089 melanoma patients. European Journal of Cancer. 71. 70–79. 51 indexed citations
3.
4.
Loquai, Carmen, Marlene Garzarolli, Martin Kaatz, et al.. (2016). Risk of interactions between complementary and alternative medicine and medication for comorbidities in patients with melanoma. Medical Oncology. 33(5). 52–52. 28 indexed citations
5.
Kaehler, Katharina C., Oliver Politz, David Henderson, et al.. (2015). Novel DNA methylation markers with potential prognostic relevance in advanced malignant melanoma identified using COBRA assays. Melanoma Research. 25(3). 225–231. 7 indexed citations
6.
Goldinger, Simone M., Lisa Zimmer, Carsten Schulz, et al.. (2013). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer. 50(2). 406–410. 19 indexed citations
7.
Mangana, Joanna, Simone M. Goldinger, Katja Schindler, et al.. (2013). Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?. Journal of Clinical Oncology. 31(15_suppl). 9025–9025. 5 indexed citations
8.
Egberts, Friederike, Ralf Gutzmer, Selma Ugurel, et al.. (2011). Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial. Annals of Oncology. 22(7). 1667–1674. 26 indexed citations
9.
Kaehler, Katharina C., Friederike Egberts, & Axel Hauschild. (2010). Electrochemotherapy in Symptomatic Melanoma Skin Metastases: Intraindividual Comparison with Conventional Surgery. Dermatologic Surgery. 36(7). 1200–1202. 19 indexed citations
10.
Kaehler, Katharina C., Sarah Piel, Elisabeth Livingstone, et al.. (2010). Update on Immunologic Therapy With Anti–CTLA-4 Antibodies in Melanoma: Identification of Clinical and Biological Response Patterns, Immune-Related Adverse Events, and Their Management. Seminars in Oncology. 37(5). 485–498. 106 indexed citations
11.
Kaehler, Katharina C., Friederike Egberts, Paul Lorigan, & Axel Hauschild. (2009). Anti-CTLA-4 therapy-related autoimmune hypophysitis in a melanoma patient. Melanoma Research. 19(5). 333–334. 25 indexed citations
12.
Kaehler, Katharina C., Vernon K. Sondak, Dirk Schadendorf, & Axel Hauschild. (2009). Pegylated interferons: Prospects for the use in the adjuvant and palliative therapy of metastatic melanoma. European Journal of Cancer. 46(1). 41–46. 12 indexed citations
13.
Dummer, Reinhard, Axel Hauschild, Juergen C. Becker, et al.. (2008). An Exploratory Study of Systemic Administration of the Toll-like Receptor-7 Agonist 852A in Patients with Refractory Metastatic Melanoma. Clinical Cancer Research. 14(3). 856–864. 95 indexed citations
14.
Spieth, Konstanze, Roland Kaufmann, Reinhard Dummer, et al.. (2008). Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Annals of Oncology. 19(4). 801–806. 23 indexed citations
15.
Egberts, Friederike, et al.. (2008). Long-Term Survival Analysis in Metastatic Melanoma: Serum S100B Is an Independent Prognostic Marker and Superior to LDH. Onkologie. 31(7). 380–384. 37 indexed citations
16.
Hauschild, Axel, Reinhard Dummer, Selma Ugurel, et al.. (2008). Combined treatment with pegylated interferon–α‐2a and dacarbazine in patients with advanced metastatic melanoma. Cancer. 113(6). 1404–1411. 18 indexed citations
17.
Hauschild, Axel, Uwe Trefzer, Claus Garbe, et al.. (2008). Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma. Melanoma Research. 18(4). 274–278. 69 indexed citations
18.
Egberts, Friederike, Katharina C. Kaehler, Jochen Brasch, et al.. (2008). Multiple skin metastases of malignant melanoma with unusual clinical and histopathologic features in an immunosuppressed patient. Journal of the American Academy of Dermatology. 58(5). 880–884. 5 indexed citations
19.
Kaehler, Katharina C., Paul Russo, D. Katenkamp, et al.. (2008). Melanocytic schwannoma of the cutaneous and subcutaneous tissues: three cases and a review of the literature. Melanoma Research. 18(6). 438–442. 28 indexed citations
20.
Hauschild, Axel, Uwe Trefzer, Claus Garbe, et al.. (2006). A phase II multicenter study on the histone deacetylase (HDAC) inhibitor MS-275, comparing two dosage schedules in metastatic melanoma. Journal of Clinical Oncology. 24(18_suppl). 8044–8044. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annette Stein Breakdown of academic impact, for papers by Chao Yao Breakdown of academic impact, for papers by Ying Lu Breakdown of academic impact, for papers by I Spuz̈ić Breakdown of academic impact, for papers by Xiaoling Yu Breakdown of academic impact, for papers by Antônio da Silva Breakdown of academic impact, for papers by Masayuki Ishizaki Breakdown of academic impact, for papers by Hongyu Zhao Breakdown of academic impact, for papers by Mariola Sadowska Breakdown of academic impact, for papers by Leslie Douglas
Rankless by CCL
2026